Bevacizumab: all 1,786 studies that test it

Page 2 of 18. Open to participants first (285), then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerRecruitingNCT07059845Phase 2
• Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver TransplantRecruitingNCT07059494Phase 4
• FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung AdenocarcinomaRecruitingNCT07058428Phase 3
• A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial CancerRecruitingNCT07054567Phase 2
• A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian CancerRecruitingNCT07042802Phase 1/2
• FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular CarcinomaRecruitingNCT07012798Phase 2
• QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRCNot yet recruitingNCT07009145Phase 2
• Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver MetastasisNot yet recruitingNCT07007728Phase 2
• Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical StudyNot yet recruitingNCT07004335Phase 4
• FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver MetastasisRecruitingNCT06988852Phase 2
• A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT06986785Phase 2
• A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.Not yet recruitingNCT06982924Phase 2
• Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast CancerRecruitingNCT06976944Phase 2
• A Study to Determine the Safety and Efficacy of Bevacizumab Administered Via Injection Into the Shoulder Joint of Participants With Adhesive Capsulitis (Frozen Shoulder)RecruitingNCT06976671Phase 2
• Autophagy Maintenance (AUTOMAIN)RecruitingNCT06971744Phase 2
• Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian CancerRecruitingNCT06954584Phase 3
• Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)RecruitingNCT06952452Phase 3
• A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant TumourRecruitingNCT06915142Phase 2
• Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersRecruitingNCT06906341Phase 2
• Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06893887Not applicable
• Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain MetastasesRecruitingNCT06888817Phase 3
• CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal CancerRecruitingNCT06881537Phase 2
• The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in AdultsNot yet recruitingNCT06876701Early Phase 1
• Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal CancerNot yet recruitingNCT06872606Phase 2
• A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingNCT06843447Phase 1/2
• SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.Not yet recruitingNCT06835179Phase 2
• A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruitingNCT06820463Phase 2
• First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian CancerRecruitingNCT06799065Phase 1/2
• A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)RecruitingNCT06796907Phase 1/2
• The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)RecruitingNCT06789757Phase 2
• PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLMRecruitingNCT06788171Phase 2
• QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBCRecruitingNCT06786026Phase 2
• Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LVRecruitingNCT06782685Phase 1/2
• A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLCRecruitingNCT06775275Phase 2
• HS-10502 Combination Treatment in Patients With Advanced Solid TumorsRecruitingNCT06769425Phase 1
• Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expressionRecruitingNCT06749860Phase 2
• Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the BrainRecruitingNCT06747728Not applicable
• PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCCRecruitingNCT06742424Phase 2
• Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian CancerRecruitingNCT06735326Phase 2
• Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain MetastasisRecruitingNCT06718933Phase 1/2
• JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)RecruitingNCT06703073Phase 2
• JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: BevacizumabRecruitingNCT06701656Phase 2
• Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal CancerRecruitingNCT06696768Phase 1
• SHR-1701 Combined with SHR2554 and BP102 for MCRCNot yet recruitingNCT06679673Phase 2
• Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLCRecruitingNCT06663306Phase 1
• NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot yet recruitingNCT06650709Phase 2
• Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line TreatmentRecruitingNCT06642844Phase 3
• Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral CurcuminRecruitingNCT06595355Phase 2/3
• Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerRecruitingNCT06580314Phase 3
• Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial OriginRecruitingNCT06576037Phase 1
• CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLCNot yet recruitingNCT06557096Early Phase 1
• A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1
• External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical CancerRecruitingNCT06543576Phase 1/2
• Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMRecruitingNCT06543069Phase 2
• Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or CetuximabRecruitingNCT06540326Phase 2
• Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast CancerNot yet recruitingNCT06539559Phase 2
• Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal MetastasesNot yet recruitingNCT06537297Phase 2
• A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With AdebrelimabNot yet recruitingNCT06513221Phase 2
• A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer PatientsRecruitingNCT06497985Phase 3
• Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingNCT06492421Phase 2
• Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2
• First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal CancerNot yet recruitingNCT06491355Phase 2
• Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal MetastasisEnrolling by invitationNCT06487715Phase 2
• Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain MetastasesRecruitingNCT06471465Phase 3
• A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRecruitingNCT06469281Phase 1
• Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical CancerRecruitingNCT06459687Phase 3
• Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian CancerNot yet recruitingNCT06446206Phase 2
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingNCT06445062Phase 1/2
• Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 FusionRecruitingNCT06439485Phase 1/2
• Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal CancerNot yet recruitingNCT06434090Phase 1/2
• The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant AscitesRecruitingNCT06433869Phase 2
• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Phase 1/2
• SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal CancerNot yet recruitingNCT06373133Phase 1/2
• Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal CarcinomaNot yet recruitingNCT06364826Phase 2
• A Study of SC-0191 in Subjects With Metastatic Colorectal CancerNot yet recruitingNCT06363552Phase 2
• SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain MetastasesNot yet recruitingNCT06361979Phase 2
• Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Phase 2
• A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.RecruitingNCT06349044Not applicable
• Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal CancerNot yet recruitingNCT06341309Phase 1/2
• Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal CancerRecruitingNCT06341296Phase 2
• Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular CarcinomaRecruitingNCT06339424Phase 2
• Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNARecruitingNCT06307249Phase 1
• A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCCRecruitingNCT06294548Phase 1/2
• TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal CancerRecruitingNCT06293014Phase 2
• Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06285019Phase 2
• Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal CancerRecruitingNCT06282445Phase 2
• Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC PatientsRecruitingNCT06280495Phase 2/3
• DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)RecruitingNCT06276283Phase 2
• Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous MalformationsRecruitingNCT06264531Phase 2/3
• Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerRecruitingNCT06245356Phase 2
• Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical CarcinomaRecruitingNCT06241235Phase 1/2
• A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06233994Not applicable
• Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal CancerRecruitingNCT06225622Phase 1
• Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal CancerRecruitingNCT06218810Phase 2
• SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain MetastasesNot yet recruitingNCT06210438Phase 2
• Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal CancerNot yet recruitingNCT06192680Phase 2
• Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal CancerRecruitingNCT06184698Phase 2
• Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesRecruitingNCT06163820Phase 1/2
• A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & SmokerRecruitingNCT06156527Phase 2
• Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain MetastasesRecruitingNCT06152822Phase 2

← Bevacizumab overview